Atossa Therapeutics Inc Stock Price, News & Analysis

Atossa Therapeutics, Inc. (Nasdaq: ATOS) will hold a webinar on June 9, 2021, at 8 am PT to discuss final data from its Phase 2 study of Endoxifen for breast cancer patients before surgery. The event will feature key executives, including Dr. Steven Quay, and will allow participants to engage with the management team. The company focuses on developing innovative therapies for oncology and infectious diseases, particularly breast cancer and COVID-19. Interested attendees can register via Tribe Public's platform.

Atossa Therapeutics, led by Dr. Steven Quay, published research challenging the claim that the Wuhan Institute of Virology had no COVID-19 cases. The study highlights a statistical improbability given the 4.4% prevalence of COVID-19 in Wuhan during early 2020. The researchers argue that proper testing would likely have revealed positive cases among the 590 staff members at WIV. This analysis raises serious questions about the integrity of WIV's reported COVID cases.

Physician-Scientist Dr. Steven C. Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), has been invited to brief U.S. Congress on his research concerning the origins of COVID-19. The virtual meeting will occur on May 24, 2021, where Dr. Quay will discuss evidence supporting the theory of a laboratory-origin virus from Wuhan, China. He contends existing data indicates a lab-leak scenario rather than natural zoonosis. The briefing aims to inform congressional members about these findings, which could influence future safety measures against pandemics.

Atossa Therapeutics (Nasdaq: ATOS) reported its Q1 2021 financial results, revealing no sustainable revenue and cash reserves of approximately $137.7 million. The company concluded a Phase 2 study for oral Endoxifen, which showed positive results, and received FDA clearance for expanded access treatment in an ovarian cancer patient. Operating expenses increased by 20% to $3.5 million, driven by a 47% rise in R&D costs. The company plans to expand clinical studies and explore new opportunities moving forward.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced its participation in the Investor Summit Conference on May 18, 2021. CEO Dr. Steven Quay and CFO Kyle Guse will present at 8:45 am ET. The company focuses on developing innovative medicines for unmet medical needs, particularly in oncology and infectious diseases, including breast cancer and COVID-19. Investors can request one-on-one meetings with management after the presentation. For more details, visit Atossa's website.

Atossa Therapeutics (Nasdaq: ATOS) urges stockholders to participate in voting for proposals in its proxy statement ahead of the annual stockholder meeting on May 14, 2021. As of March 24, 2021, approximately 17.3 million shares are under lock-up and voting agreements. The company focuses on developing innovative treatments for unmet medical needs in oncology and infectious diseases, particularly breast cancer and COVID-19. For more information on voting and proposals, stockholders can refer to the proxy statement linked in the announcement.

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical firm, announced participation by CEO Dr. Steven Quay in a panel discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021, at 10:00 AM ET. The panel, titled 'Investing in the Emerald City of Oncology Innovation,' will include experts from various venture investment funds. Atossa focuses on developing innovative treatments for oncology and infectious diseases, particularly breast cancer and COVID-19. For registration, visit their official site.

Atossa Therapeutics (Nasdaq: ATOS) announces an ovarian cancer patient has started treatment with its proprietary oral Endoxifen, following FDA approval via the expanded access pathway. This patient, treated by Dr. Barbara Goff at the University of Washington, previously did not tolerate tamoxifen. Molecular testing indicated that Endoxifen combined with alpelisib yielded a significant tumor response. The FDA's expanded access allows use solely for this patient, and Atossa is considering additional clinical studies.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported its 2020 financial results, highlighting significant advancements in its clinical programs, particularly for Endoxifen and AT-301. The company concluded a Phase 2 study for Endoxifen early due to positive interim results, accelerated its development plans, and received FDA approval for expanded access in ovarian cancer treatment. Operating expenses declined 15% to approximately $14.6 million, with R&D expenses slightly decreasing. At year-end, Atossa held about $39.7 million in cash, positioning itself well for future opportunities.